De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Genetic Signatures Toekomstige groei

Future criteriumcontroles 6/6

Genetic Signatures zal naar verwachting groeien in winst en omzet met respectievelijk 98.6% en 41.9% per jaar. De winst per aandeel zal naar verwachting groeien met 101.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 24.7% zijn.

Belangrijke informatie

98.6%

Groei van de winst

101.2%

Groei van de winst per aandeel

Life Sciences winstgroei	19.9%
Inkomstengroei	41.9%
Toekomstig rendement op eigen vermogen	24.7%
Dekking van analisten	Low
Laatst bijgewerkt	03 Sep 2024

Recente toekomstige groei-updates

Recent updates

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

Jun 14

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Mar 08

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Nov 14

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Oct 10

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Jun 29

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 28

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

Feb 25

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

Feb 07

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Jan 17

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

Dec 27

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

Dec 06

Winst- en omzetgroeiprognoses

ASX:GSS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (AUD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2027	72	20	13	19	1
6/30/2026	46	3	-5	1	1
6/30/2025	24	-11	-15	-10	1
6/30/2024	14	-18	-15	-10	N/A
3/31/2024	15	-18	-16	-10	N/A
12/31/2023	16	-18	-16	-10	N/A
9/30/2023	19	-16	-18	-11	N/A
6/30/2023	22	-14	-21	-12	N/A
3/31/2023	23	-11	-16	-8	N/A
12/31/2022	24	-8	-11	-3	N/A
9/30/2022	30	-3	-2	3	N/A
6/30/2022	35	3	7	10	N/A
3/31/2022	33	3	4	7	N/A
12/31/2021	31	2	1	4	N/A
9/30/2021	30	2	0	4	N/A
6/30/2021	28	2	-1	4	N/A
3/31/2021	29	3	-3	2	N/A
12/31/2020	29	5	-5	-1	N/A
9/30/2020	21	1	-9	-5	N/A
6/30/2020	14	-2	-12	-9	N/A
3/31/2020	11	-3	-8	-6	N/A
12/31/2019	7	-4	-4	-3	N/A
9/30/2019	7	-4	-3	-3	N/A
6/30/2019	7	-3	-3	-2	N/A
3/31/2019	7	-3	-3	-2	N/A
12/31/2018	6	-3	-3	-2	N/A
9/30/2018	5	-3	-4	-3	N/A
6/30/2018	5	-3	-4	-4	N/A
3/31/2018	5	-3	N/A	-3	N/A
12/31/2017	5	-3	N/A	-3	N/A
9/30/2017	4	-3	N/A	-3	N/A
6/30/2017	4	-3	N/A	-3	N/A
3/31/2017	4	-3	N/A	-2	N/A
12/31/2016	4	-3	N/A	-2	N/A
9/30/2016	3	-3	N/A	-2	N/A
6/30/2016	3	-3	N/A	-3	N/A
3/31/2016	3	-3	N/A	-3	N/A
12/31/2015	3	-3	N/A	-3	N/A
9/30/2015	2	-3	N/A	-3	N/A
6/30/2015	2	-3	N/A	-3	N/A
6/30/2014	1	-2	N/A	-1	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat GSS de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 2.4% ).

Winst versus markt: Er wordt verwacht dat GSS de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat GSS binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van GSS ( 41.9% per jaar) zal naar verwachting sneller groeien dan de markt Australian ( 5.5% per jaar).

Hoge groei-inkomsten: De omzet van GSS ( 41.9% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen GSS zal naar verwachting over 3 jaar hoog zijn ( 24.7 %)

Genetic Signatures Toekomstige groei

Future criteriumcontroles 6/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 60%

Consensus revenue estimates fall by 28%

Consensus revenue estimates decrease by 31%

Price target decreased by 20% to AU$0.90

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

Recent updates

New minor risk - Market cap size

Consensus EPS estimates fall by 60%

Full year 2024 earnings: EPS misses analyst expectations

Genetic Signatures Limited Announces Changes to Board of Directors

Getting In Cheap On Genetic Signatures Limited (ASX:GSS) Might Be Difficult

New major risk - Shareholder dilution

Genetic Signatures Limited Announces That the US Food & Drug Administration Has Cleared the Company's Easyscreen™ Gastrointestinal Parasite Detection Kit and Gs1 Automated Workflow for Marketing and Sale in the US

After Leaping 42% Genetic Signatures Limited (ASX:GSS) Shares Are Not Flying Under The Radar

Director recently bought AU$59k worth of stock

New minor risk - Profitability

Consensus revenue estimates fall by 28%

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.979326 million.

Genetic Signatures Limited has completed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Consensus revenue estimates decrease by 31%

New minor risk - Shareholder dilution

Genetic Signatures Limited has filed a Follow-on Equity Offering in the amount of AUD 7.97898 million.

Price target decreased by 20% to AU$0.90

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Genetic Signatures Limited (ASX:GSS)

Genetic Signatures Limited, Annual General Meeting, Nov 29, 2023

Now 21% undervalued after recent price drop

Full year 2023 earnings released: AU$0.098 loss per share (vs AU$0.021 profit in FY 2022)

New minor risk - Financial data availability

Genetic Signatures Limited Appoints Karl Pechmann as Chief Financial Officer , Effective 26 June 2023

Consensus EPS estimates fall by 37%

Price target increased by 8.0% to AU$0.95

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.033 profit in 1H 2022)

Less than half of directors are independent

Price target decreased to AU$0.90

Genetic Signatures Limited, Annual General Meeting, Nov 16, 2022

Genetic Signatures Limited (ASX:GSS) Investors Are Less Pessimistic Than Expected

Full year 2022 earnings released: EPS: AU$0.021 (vs AU$0.012 in FY 2021)

Genetic Signatures Limited Announces Clinical Trial Recruitment Completed for US Enteric Kit

Genetic Signatures Limited Announces Appointment of Caroline Waldron as New Non-Executive Director

Price target decreased to AU$1.38

Less than half of directors are independent

First half 2022 earnings: EPS and revenues exceed analyst expectations

Genetic Signatures Limited Announces 3base® SARS-CoV-2 diagnostic kit registered by TGA for saliva samples

Full year 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Price target decreased to AU$2.20

One Genetic Signatures Limited (ASX:GSS) Analyst Just Made A Major Cut To Next Year's Estimates

Consensus revenue estimates fall to AU$28.0m

New 90-day low: AU$1.58

Genetic Signatures (ASX:GSS) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AU$3.20: That's What Analysts Think Genetic Signatures Limited (ASX:GSS) Is Worth After Its Latest Results

First half 2021 earnings released: EPS AU$0.032 (vs AU$0.021 loss in 1H 2020)

Revenue beats expectations, earnings disappoint

What Kind Of Shareholders Hold The Majority In Genetic Signatures Limited's (ASX:GSS) Shares?

What Does Genetic Signatures' (ASX:GSS) CEO Pay Reveal?

Genetic Signatures' (ASX:GSS) Wonderful 522% Share Price Increase Shows How Capitalism Can Build Wealth

New 90-day low: AU$1.65

Genetic Signatures (ASX:GSS) Is In A Strong Position To Grow Its Business

New 90-day low - AU$1.95

Full year earnings released - AU$0.016 loss per share

New 90-day high - AU$2.62

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven